Invention Grant
- Patent Title: Pyrrolidine derivatives as PPAR agonists
-
Application No.: US16317510Application Date: 2017-07-12
-
Publication No.: US10526320B2Publication Date: 2020-01-07
- Inventor: Zhiliang Yuan , Chaofeng Long , Zhigan Jiang , Xiaoxin Chen , Haiying He , Xing Liu , Xiao Zhang , Zhiqiang Liu , Yan Wang , Leilei Gao , Zhen Gong , Jian Li , Shuhui Chen
- Applicant: GUANGDONG RAYNOVENT BIOTECH CO., LTD.
- Applicant Address: CN Guangdong
- Assignee: GUANGDONG RAYNOVENT BIOTECH CO., LTD.
- Current Assignee: GUANGDONG RAYNOVENT BIOTECH CO., LTD.
- Current Assignee Address: CN Guangdong
- Agency: D'Ambrosio & Menon, PLLC
- Agent Usha Menon
- Priority: CN201610547500 20160712; CN201710087306 20170217
- International Application: PCT/CN2017/092583 WO 20170712
- International Announcement: WO2018/010656 WO 20180118
- Main IPC: A61P1/16
- IPC: A61P1/16 ; A61P3/06 ; A61P5/50 ; A61P9/10 ; C07D207/08 ; C07D401/12 ; C07D403/06 ; C07D403/12 ; C07D405/04 ; C07D409/06
Abstract:
The present invention discloses a class of pyrrolidine derivatives as PPAR agonist, and their use for the treatment of some diseases of PPAR receptor-associated pathways (such as nonalcoholic steatohepatitis and concurrent fibrosis, insulin resistance, primary biliary cholangitis, dyslipidemia, hyperlipidemia, hypercholesterolemia, atherosclerosis, hypertriglyceridemia, cardiovascular disease, obesity or the like). In particular, the present invention discloses a compound represented by Formula (I) or a pharmaceutically acceptable salt thereof.
Public/Granted literature
- US20190225597A1 PYRROLIDINE DERIVATIVES AS PPAR AGONISTS Public/Granted day:2019-07-25
Information query
